U.S. Markets open in 4 hrs 16 mins

GW Pharmaceuticals plc (GWPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
140.08+10.37 (+7.99%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close129.71
Open129.74
Bid0.00 x 1000
Ask190.00 x 900
Day's Range129.74 - 140.43
52 Week Range67.98 - 141.98
Volume650,626
Avg. Volume422,841
Market Cap4.172B
Beta (5Y Monthly)1.96
PE Ratio (TTM)N/A
EPS (TTM)-1.73
Earnings DateFeb 23, 2021 - Mar 01, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est184.00
  • GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference
    GlobeNewswire

    GW Pharmaceuticals to Present at the Evercore ISI 2020 Healthcare Conference

    LONDON and CARLSBAD, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Evercore ISI HealthCONx Conference on Wednesday, December 2, 2020 at 1:50 pm EST. A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Investors section under Events & Presentations. A replay will be available soon after the live presentation.About GW Pharmaceuticals plc and Greenwich Biosciences, Inc. Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, EPIDIOLEX® (cannabidiol) oral solution, is commercialized in the U.S. by its U.S. subsidiary Greenwich Biosciences for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome, or tuberous sclerosis complex (TSC) in patients one year of age and older. This product has received approval in the European Union under the tradename EPIDYOLEX® for the adjunctive treatment of seizures associated with LGS or Dravet syndrome in conjunction with clobazam in patients two years and older and is under EMA review for the treatment of TSC. The Company has a deep pipeline of additional cannabinoid product candidates, in particular nabiximols, for which the Company is advancing multiple late-stage clinical programs in order to seek FDA approval in the treatment of spasticity associated with multiple sclerosis and spinal cord injury. The Company has additional cannabinoid product candidates in clinical trials for autism and schizophrenia. For further information, please visit www.gwpharm.com.Enquiries:GW Pharmaceuticals plc    Scott Giacobello, Chief Financial Officer  760 795 2200

  • When Can We Expect A Profit From GW Pharmaceuticals plc (NASDAQ:GWPH)?
    Simply Wall St.

    When Can We Expect A Profit From GW Pharmaceuticals plc (NASDAQ:GWPH)?

    With the business potentially at an important milestone, we thought we'd take a closer look at GW Pharmaceuticals...

  • Findit Features Members Global WholeHealth Partners, WynCore and OTC Tip Reporter
    ACCESSWIRE

    Findit Features Members Global WholeHealth Partners, WynCore and OTC Tip Reporter

    ATLANTA, GA / ACCESSWIRE / November 17, 2020 / Findit, Inc.